OmniAb SPAC Presentation Deck

THE POWER OF OMNIAB PARTNER CASE STUDIES Partner A Emerging Biotech Novel multi-transmembrane target for triple negative breast cancer All previously-known antibodies to target could only bind to denatured or fixed form, therefore unsuitable for therapeutic use Our antigen tech was applied to deliver mg-scale quantities of purified receptor in native conformation for immunization and screening OmniChicken immunization led to discovery of a large and diverse panel of fully-human antibodies capable of binding target on live tissues Partner B Big Pharma • Growth factor target, highly conserved among mammals Human version of target non- immunogenic in other rodents; no titer achieved despite numerous immunization attempts by partner Genetic knockout of target gene attempted in mice but was lethal OmniChicken immunization led to robust titers and diverse antibody panels >90% of sequences recovered had excellent developability profiles based on multi-parameter in-silico analysis Partner C Established Biotech • Partner has history of success in developing antibodies, with large discovery group and expanding novel biology ● ● Partner needed a flexible, scalable antibody discovery solution to start dozens of new programs every year Deep collaboration to develop next generation rodents, which were tested in parallel with active novel programs OmniAb wholly owns rights to next- generation animals and can include them in the OmniAb technology offering to other partners Partner D Global Pharma ● Asia-based global pharma player that is establishing a new and substantial presence in antibody space with large investment and expansion of global antibody team Partner needed OmniAb's antibody discovery engine to power their growth Selected OmniAb as core technology to feed robust discovery and development efforts • Developed three-way collaboration with deep repertoire analysis to rapidly identify best binders for bispecific antibodies 23 OmniAb

View entire presentation